Why the study?
HCM is determined by altered extracellular matrix collagen turnover, and this systematic review aimed to thoroughly summarize and discuss existing knowledge of the MMPs profile in patients with HCM.
Are matrix metalloproteinase (MMP) levels altered in patients with hypertrophic cardiomyopathy compared to healthy subjects?
Are matrix metalloproteinase (MMP) levels altered in patients with hypertrophic cardiomyopathy compared to healthy subjects?
Answers are grounded in this paper and cite their sources.
MMP levels, particularly MMP2, are elevated in patients with hypertrophic cardiomyopathy and may serve as non-invasive biomarkers for evaluating extracellular matrix collagen turnover.
Hypertrophic cardiomyopathy (HCM) is a genetic condition determined by an altered collagen turnover of the extracellular matrix. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) are abnormally released in patients with HCM. The purpose of this systematic review was to thoroughly summarize and discuss the existing knowledge of MMPs profile in patients with HCM. All studies meeting the inclusion criteria (detailed data regarding MMPs in patients with HCM) were selected, after screening the literature from July 1975 to November 2022. Sixteen trials that enrolled a total of 892 participants were included. MMPs-particularly MMP2-levels were found higher in HCM patients compared to healthy subjects. MMPs were used as biomarkers after surgical and percutaneous treatments. Understanding the molecular processes that control the cardiac ECM's collagen turnover allows for a non-invasive evaluation of HCM patients through the monitoring of MMPs and TIMPs.
No takes yet. Share an insight, caveat, or question.
Serraino et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: